Neurofilament light chain (NfL) remains the most validated biomarker for ALS, with its elevated CSF and serum levels correlating with disease progression rate (ρ = 0.72) and survival [101,102] (Figure 6). Here, NEFL is linked to amyotrophic lateral sclerosis.